TRACON to Report Fourth Quarter and Full Year 2020 Financial Results and Company Highlights on February 25, 2021
February 18 2021 - 8:05AM
TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage
biopharmaceutical company focused on the development and
commercialization of novel targeted cancer therapeutics and
utilizing a cost efficient, CRO-independent product development
platform to partner with ex-U.S. companies to develop and
commercialize innovative products in the U.S., announced today that
it will report its fourth quarter and full year 2020 financial and
operating results after the close of U.S. financial markets on
Thursday, February 25, 2021. In addition, management will host a
conference call to provide an update on corporate activities and
discuss the financial results.
Conference call and webcast: |
Date: |
February 25, 2021 |
Time: |
4:30 pm Eastern Time (1:30 pm Pacific Time) |
Dial-in: |
(855) 779-9066 (Domestic) or (631) 485-4859 (International) |
Passcode: |
5681569 |
Via web: |
www.traconpharma.com; “Events and Presentations” section within the
“Investors” section |
A replay of the webcast will be available for 60
days on the website.
About TRACON
TRACON develops targeted therapies for cancer
utilizing a capital efficient, CRO independent, product development
platform. The Company’s clinical-stage pipeline includes:
Envafolimab, a PD-L1 single-domain antibody given by rapid
subcutaneous injection that is being studied in the pivotal
ENVASARC trial for sarcoma; TRC253, a Phase 3 ready small molecule
drug candidate for the treatment of prostate cancer; TRC102, a
Phase 2 small molecule drug candidate for the treatment of lung
cancer; and TJ004309, a CD73 antibody in Phase 1 development for
the treatment of advanced solid tumors. TRACON is actively seeking
additional corporate partnerships whereby it leads U.S. regulatory
and clinical development and shares in the cost and risk of
clinical development and leads U.S. commercialization. In
these partnerships TRACON believes it can serve as a solution for
companies without clinical and commercial capabilities in the
U.S. To learn more about TRACON and its product pipeline,
visit TRACON's website at www.traconpharma.com.
Company Contact: |
Investor Contact: |
Mark Wiggins |
Brian Ritchie |
Chief Business Officer |
LifeSci Advisors LLC |
(858) 251-3492 |
212-915-2578 |
mwiggins@traconpharma.com |
|
TRACON Pharmaceuticals (NASDAQ:TCON)
Historical Stock Chart
From Aug 2024 to Sep 2024
TRACON Pharmaceuticals (NASDAQ:TCON)
Historical Stock Chart
From Sep 2023 to Sep 2024